Dapagliflozin associated with lower risk for all-cause mortality in type 2 diabetes regardless of CVD risk, study finds
The population-based retrospective cohort study included 22,124 type 2 diabetes patients from a British national primary care database, 4,444 of whom had taken dapagliflozin.
Adults with type 1 and type 2 diabetes should aim to spend more than 70% of each day in the target range of 70 to 180 mg/dL (3.9 to 10.0 mmol/L), which corresponds to an HbA1c level of about 7%, the consensus report said.
Supplemental triglyceride-lowering therapy may lower CVD risk in statin-treated patients with diabetic dyslipidemia, study finds
The rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes was 27% lower in participants with dyslipidemia randomized to fenofibrate than among those randomized to placebo.
Mean HbA1c was 5.7% in the African-American participants with sickle cell trait and 6.0% in those without, despite similar mean fasting and two-hour glucose values.
ACP recommended that clinicians prescribe metformin for type 2 diabetes when pharmacologic therapy is needed to improve glycemic control in a strong recommendation based on moderate-quality evidence.
The position statement recommends that physicians consider assessing cognitive capacities and symptoms of diabetes distress, depression, anxiety, and disordered eating at the initial visit and at periodic intervals.
The study included patients 65 years of age and older with type 1 or type 2 diabetes admitted to a Veterans Affairs nursing home, and they were categorized by baseline HbA1c (6.0% to 6.9%, 7.0% to 7.9%, 8.0% to 8.9%, and 9.0% or higher).
The intervention for Medicare beneficiaries with prediabetes includes at least 16 weekly hour-long sessions over months 1 to 6 and at least 6 monthly maintenance sessions over months 6 to 12.
Our findings also highlight the need for early intervention aimed to reduce risk factors for overweight or obesity in type 2 diabetic individuals to preserve their brain structure and cognitive function,”
Continuous glucose monitoring associated with lower HbA1c in type 1 diabetes treated with insulin injection
An editorial accompanying the two trials of continuous glucose monitoring stressed that the physicians involved had extensive experience with the technology and noted that the necessary changes in lifestyle and insulin dosing can be variable and